3MM.F ADVICENNE (PROM.) EO-20
- Market cap
- EUR 9.95M
- P/E
- 9.3x
- P/B
- 131.80x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 3MM.F undervalued?
Graham numberThe Graham number of ADVICENNE (PROM.) EO-20 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ADVICENNE (PROM.) EO-20 fundamental analysis
No fundamental analysis for ADVICENNE (PROM.) EO-20 yet.
ADVICENNE (PROM.) EO-20 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ADVICENNE (PROM.) EO-20
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizur…
Full company profileADVICENNE (PROM.) EO-20 financial statements
ADVICENNE (PROM.) EO-20 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.69M | 3.72M | 4.46M | 4.97M | 6.01M |
| Gross Profit | 1.72M | -5.38M | -2.22M | -1.18M | -922K |
| Operating Income | -12.4M | -10.3M | -6.48M | -9.06M | -8.36M |
| EBITDA | - | -9.85M | -6.30M | -6.32M | -7.86M |
| Net Income | -12.4M | -10.3M | -7.53M | -6.46M | -9.53M |
| EPS | -1.23 | -1.01 | -0.61 | -0.53 | -0.66 |
| Balance Sheet | |||||
| Total Assets | 18.9M | 13.8M | 12.4M | 9.51M | 7.14M |
| Total Liabilities | 18.6M | 24.3M | 25.0M | 28.6M | 33.5M |
| Shareholders' Equity | 309K | -10.5M | -12.6M | -19.1M | -26.4M |
| Cash & Short-term Investments | 12.7M | 7.32M | 4.25M | 3.25M | 1.35M |
| Cash Flow | |||||
| Operating Cash Flow | -12.5M | -9.32M | -6.04M | -762K | -3.73M |
| Capital Expenditure | 297K | 115K | 1.23M | 91.0K | 382K |
| Free Cash Flow | -12.8M | -9.32M | -7.27M | -853K | -4.11M |
| Ratios | |||||
| ROE | -4,021.7% | - | - | - | - |
| ROA | -65.8% | -74.3% | -60.8% | -68.0% | -133.5% |
| Net Profit Margin | -462.1% | -276.4% | -168.9% | -130.0% | -158.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ADVICENNE (PROM.) EO-20 dividends
ADVICENNE (PROM.) EO-20 has not paid dividends in the last 5 fiscal years.
Who owns ADVICENNE (PROM.) EO-20
- Insiders 4.47%
- Institutions 38.49%
- Public & others 57.04%
- Shares outstanding 15.2M
- Free float 8.88M
ADVICENNE (PROM.) EO-20 company profile
- Company name
- ADVICENNE (PROM.) EO-20
- Ticker
- 3MM.F
- ISIN
- FR0013296746
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- 262 Rue du Faubourg Saint-Honore, Paris, France, 75008
- Phone
- 33 1 85 73 36 20
- Website
- advicenne.com
About ADVICENNE (PROM.) EO-20
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
ADVICENNE (PROM.) EO-20 management
6- Mr. Didier LaurensGeneral Director & Chairman of the Board · born 1966
- Ms. Delphine Dumas-CivardDeputy Chief Executive Officer
- Ms. Isabelle KervellaChief Financial Officer
- Dr. Andre Ulmann M.D., Ph.D.Chief Medical Officer, Censor & Director · born 1949
- Ms. Hege HellstromChief Commercial Officer · born 1965
- Mr. Robbie McCarthyGeneral Manager of Advicenne Inc.